Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
In conclusion, tanezumab 10 mg significantly improved pain and function vs placebo in patients with difficult-to-treat chronic low back pain. Tanezumab was associated with a low rate of joint safety events, some requiring joint replacement.
Source: Pain - Category: Anesthesiology Tags: Research Paper Source Type: research
More News: Anesthesiology | Back Pain | Chronic Pain | Disability | Low Back Pain | Orthopaedics | Pain | Study | Tramadol